摘要
目的 探讨血清可溶性白细胞介素２ 受体（ＳＩＬ－ ２Ｒ）与恶性肿瘤临床分期、临床疗效的关系。方法 采用双抗体夹心ＥＬＩＳＡ法测定了８２例恶性肿瘤患者血清ＳＩＬ－ ２Ｒ水平。结果 ８ 种不同恶性肿瘤患者血清ＳＩＬ－ ２Ｒ水平（６０８．０±２７５．７～１１３５．０±６５７．６Ｕ／ｍ ｌ）较之健康对照组（２５０．０±１２８．９Ｕ／ｍ ｌ）均明显升高，且与临床分期及临床疗效密切相关。结论 血清ＳＩＬ－ ２Ｒ检测有助于判断恶性肿瘤患者临床疗效、病情严重程度及估计预后。
? Objective To explore the relationship between the levels of serum soluble IL-2 receptor (SIL-2R) and clinical stages,therapeutic effects on malignant tumors.Methods The levels of serum SIL-2R in 82 patients with different types of malignant tumors were dertermined with ELISA method.Results The levels of serum SIL-2R rose remarkably (608.0±275.7～1135.0±657.6U/ml) among patients suffering from tumors as compared with the normal persons (250.0±128.9U/ml)(P<0.01);the levels of serum SIL-2R of patients with malignancy had a significant correlation with clininal stages and therapeutic effects.Conclusion The determination of serum SIL-2R can benefit the estimation about therapeutic effects,the severity of the disease and prognosis of malignant tumors. 〔
出处
《中国肿瘤临床与康复》
1999年第4期37-38,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
